Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Dual-specificity tyrosine-phosphorylated regulated kinase 1A (DYRK1A) is implicated in various diseases, making it a key target for drug development.
• Initial fragment screening identified a biaryl compound with high affinity for the DYRK1A ATP site, but lacking selectivity.

Purpose of the Study:

• To optimize a fragment hit into potent and selective DYRK1A inhibitors.
• To leverage structural differences between DYRK1A and DYRK2 to enhance inhibitor selectivity.

Main Methods:

• Fragment-based drug discovery approach.
• Structure-guided optimization of lead compounds.
• Cell-based assays and in vivo studies in animal models.
• Evaluation of drug-like properties and selectivity against DYRK2.

Main Results:

• Successfully converted a low-selectivity fragment into potent and selective DYRK1A inhibitors.
• Achieved fine-tuned selectivity by exploiting DYRK1A/DYRK2 structural variations.
• Demonstrated potent DYRK1A inhibition in vitro and in vivo.
• Observed dose-dependent tumor growth inhibition in an ovarian carcinoma model.

Conclusions:

• Developed novel, drug-like DYRK1A inhibitors with high potency and selectivity.
• Validated DYRK1A inhibition as a therapeutic strategy for ovarian carcinoma.
• These inhibitors represent promising candidates for further preclinical and clinical development.